The FDA has approved Avance® (acellular nerve allograft-arwx) for the treatment of sensory nerve discontinuity.
The FDA has approved Avance® (acellular nerve allograft-arwx) for treating sensory nerve discontinuity. Derived from cadaveric nerve tissue, Avance bridges gaps in injured peripheral nerves ...
The active fault traces on which earthquakes occur are generally not continuous 1, and are commonly composed of segments that are separated by discontinuities that appear as steps in map-view. Stress ...
(NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function, today announced that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback